SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from tenosynovial giant cell tumors (TGCT) and other macrophage-mediated diseases. The company leverages its extensive knowledge and experience in the field to develop innovative treatment options that aim to improve the quality of life for these patients. By focusing on the unique challenges posed by TGCT and similar conditions, SynOx is committed to advancing therapeutic solutions that empower patients in their treatment journeys.

The company’s approach is characterized by a strong emphasis on scientific research and development, which underpins its pipeline of products. SynOx Therapeutics is driven by a passion for life and a commitment to delivering effective therapies that can significantly impact patient outcomes. Through its dedication to understanding the mechanisms of macrophage-mediated diseases, SynOx aims to create targeted treatments that not only address the symptoms but also the underlying causes of these conditions.

Ireland

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

SynOx Therapeutics

Company Details